secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-06-12T20:11:17+00:00
Accession:  0001599298-26-000054
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics stockholders elect all nine directors, approve 8M share increase at annual meeting
--------------------------------------------------------------------------------

- All nine director nominees elected with strong support; highest withheld votes were 25M for Kenneth A. Clark.
- Ratification of PricewaterhouseCoopers as auditor passed: 677.3M for, 85K against.
- Advisory vote on named executive officer compensation passed: 622.6M for, 24.4M against.
- Plan amendment to increase authorized shares by 8M approved: 619.8M for, 27.2M against.
- Annual meeting held June 10, 2026; all proposals approved as recommended by the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000054/0001599298-26-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000054/smmt-20260610.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer